Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528957 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
NCT00528957 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 97 participants.
The verdict
NCT00528957, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
Interventions
- DRUG Zidovudine
- DRUG Tenofovir DF
- DRUG Stavudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-12-28 |
| Est. Completion | 2017-08-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528957
The ClinicalTrials.gov registry entry for NCT00528957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00528957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528957 about?
NCT00528957 is a clinical study titled "Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children". The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
What is the current status of trial NCT00528957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2006-12-28. Estimated completion is 2017-08-16.
What interventions are being tested in trial NCT00528957?
The interventions under investigation include: Zidovudine (DRUG), Tenofovir DF (DRUG), Stavudine (DRUG).
Who is sponsoring clinical trial NCT00528957?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.